Trulicity (dulaglutide) is a once-weekly injectable medication that mimics a natural gut hormone called GLP-1 to lower blood sugar in people with type 2 diabetes. It works through three simultaneous mechanisms: boosting insulin release when blood sugar is high, suppressing a hormone that raises blood sugar, and slowing how quickly food leaves your stomach. These effects combine to bring down both fasting and post-meal glucose levels.
How It Mimics a Natural Hormone
When you eat, your intestines release a hormone called GLP-1 (glucagon-like peptide-1). This hormone signals your pancreas to produce more insulin, which moves sugar out of your bloodstream and into your cells. In people with type 2 diabetes, this signaling system doesn’t work well enough on its own.
Trulicity is a lab-engineered version of GLP-1 that activates the same receptors your natural hormone would. The key difference is durability. Your body’s own GLP-1 is broken down within minutes by an enzyme called DPP-4. Dulaglutide is designed to resist that breakdown, giving it a half-life of about five days. That’s why a single injection covers a full week. Steady drug levels in your bloodstream are typically reached between the second and fourth weekly doses.
One important feature: Trulicity’s effect on insulin is glucose-dependent. It only triggers extra insulin release when your blood sugar is elevated. When glucose levels are normal, the drug doesn’t push insulin higher, which significantly lowers the risk of hypoglycemia compared to some older diabetes medications.
Three Ways It Lowers Blood Sugar
The first mechanism is increased insulin secretion. When you eat and glucose rises, Trulicity amplifies the signal telling your pancreas to release insulin. This is especially effective at controlling the blood sugar spike that follows meals.
The second is glucagon suppression. Glucagon is a hormone from your pancreas that tells your liver to dump stored sugar into the bloodstream. In type 2 diabetes, glucagon is often inappropriately high. Trulicity dials it back when blood sugar is already elevated, reducing that excess sugar release from the liver.
The third is delayed gastric emptying. Trulicity slows the rate at which food moves from your stomach into your small intestine. This means glucose from a meal enters your bloodstream more gradually instead of all at once. In clinical studies, this slowing effect was most pronounced after the first dose and lessened somewhat with continued use. In one study, six weeks of treatment at the 1.5 mg dose reduced post-meal blood sugar by about 60 mg/dL and fasting glucose by about 26 mg/dL compared to placebo.
Effects on Appetite and Weight
GLP-1 receptors aren’t only in the pancreas and gut. They’re also in the brain, particularly in a region of the hypothalamus that regulates hunger and fullness. When Trulicity activates these brain receptors, it strengthens satiety signals, essentially telling your brain you’ve had enough food before you’ve eaten as much as you normally would. Animal research shows these neurons act as a kind of pre-emptive brake on eating, sending inhibitory signals that help terminate a meal earlier.
This appetite-reducing effect means many people on Trulicity lose some weight, though the drug is approved specifically for blood sugar control, not weight loss. The weight changes tend to be modest compared to higher-dose GLP-1 medications marketed for obesity.
How Much It Lowers A1C
In clinical trials, Trulicity reduced A1C (a measure of average blood sugar over two to three months) by meaningful amounts across all doses. The 0.75 mg starting dose lowered A1C by 0.7% to 1.6%, depending on the study and what other medications patients were taking. The 1.5 mg dose showed reductions of 0.8% to 1.6%.
Higher doses approved more recently showed further improvement. In the AWARD-11 trial, patients starting with an average A1C of 8.6% saw reductions of 1.5% at the 1.5 mg dose, 1.6% at 3.0 mg, and 1.8% at 4.5 mg over 36 weeks. For context, bringing an A1C from 8.6% down to around 7% is a clinically significant change that reduces the risk of diabetes-related complications.
Cardiovascular Protection
Trulicity has benefits beyond blood sugar. The REWIND trial, published in The Lancet, followed nearly 10,000 people with type 2 diabetes for a median of 5.4 years. Those taking dulaglutide had a 12% lower risk of experiencing a major cardiovascular event (heart attack, stroke, or cardiovascular death) compared to placebo. The rate was 12.0% in the dulaglutide group versus 13.4% in the placebo group. This was notable because the study included patients with a wide range of cardiovascular risk, not just those who had already had a heart attack or stroke.
Common Side Effects
The most frequent side effects are gastrointestinal, and they’re a direct consequence of how the drug works. Slowed gastric emptying and changes in gut signaling can cause nausea, diarrhea, and vomiting. In a 52-week study of the three available doses, nausea affected about 14% to 17% of participants, diarrhea 8% to 12%, and vomiting 6% to 10%. Higher doses carried slightly higher rates of these symptoms.
For most people, GI side effects are worst in the first few weeks and improve as the body adjusts. The slowed stomach emptying also has a practical implication: other oral medications you take may be absorbed more slowly, which is worth discussing with your prescriber if you’re on time-sensitive drugs.
Dosing and Administration
Trulicity comes as a pre-filled, single-use pen that you inject under the skin once a week, on the same day each week. You can inject it in your abdomen, thigh, or upper arm, and you don’t need to take it with food. Most people start at 0.75 mg weekly, with the option to increase to 1.5 mg for better blood sugar control.
The pens should be stored in the refrigerator. If you’re traveling or refrigeration isn’t available, a pen can stay at room temperature (below 86°F or 30°C) for up to 14 total days. Those 14 days don’t have to be consecutive; you can take the pen in and out of the fridge as long as the total time at room temperature doesn’t exceed 14 days.
Safety Warnings
Trulicity carries a boxed warning about thyroid tumors. In animal studies, dulaglutide caused C-cell tumors in the thyroid glands of rats. Whether this risk translates to humans is unknown. Because of this uncertainty, Trulicity is not used in people with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. It’s also contraindicated in anyone who has had a serious allergic reaction to dulaglutide or any of its ingredients.